HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Edward S Kim Selected Research

Adenocarcinoma of Lung

11/2013Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.
1/2013CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Edward S Kim Research Topics

Disease

75Neoplasms (Cancer)
01/2023 - 01/2002
58Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/2022 - 07/2002
37Lung Neoplasms (Lung Cancer)
01/2023 - 07/2002
11Carcinogenesis
01/2018 - 01/2002
10Disease Progression
01/2022 - 08/2005
10Squamous Cell Carcinoma of Head and Neck
12/2019 - 05/2002
10Head and Neck Neoplasms (Head and Neck Cancer)
11/2015 - 05/2002
9Squamous Cell Carcinoma (Epidermoid Carcinoma)
09/2022 - 01/2003
8Exanthema (Rash)
01/2021 - 11/2008
8Mouth Neoplasms (Oral Cancer)
01/2018 - 05/2002
5Diarrhea
12/2022 - 05/2004
4Brain Neoplasms (Brain Tumor)
01/2021 - 03/2013
4Neoplasm Metastasis (Metastasis)
01/2020 - 05/2002
3Sarcoma (Soft Tissue Sarcoma)
12/2021 - 02/2012
3Fatigue
01/2021 - 12/2013
3Acne Vulgaris
01/2018 - 04/2006
3Neutropenia
04/2010 - 05/2004
3Metaplasia
02/2010 - 10/2003
2Squamous Cell Neoplasms (Squamous Cell Cancer)
09/2022 - 04/2006
2COVID-19
11/2021 - 01/2020
2Agranulocytosis (Granulocytopenia)
02/2018 - 02/2009
2Infections
02/2018 - 03/2009
2Adenocarcinoma
06/2015 - 05/2014
2Adenocarcinoma of Lung
11/2013 - 01/2013
2Colorectal Neoplasms (Colorectal Cancer)
02/2012 - 11/2010
2Hyperplasia
08/2011 - 09/2009
2Breast Neoplasms (Breast Cancer)
11/2010 - 03/2009
2Fever (Fevers)
04/2010 - 05/2004
2Leukoplakia
10/2009 - 01/2009
1Long Term Adverse Effects
06/2022
1Fibrosarcoma
06/2022

Drug/Important Bio-Agent (IBA)

23ErbB Receptors (EGF Receptor)IBA
01/2021 - 01/2003
22Biomarkers (Surrogate Marker)IBA
01/2022 - 05/2004
11Tyrosine Kinase InhibitorsIBA
06/2021 - 04/2005
10Erlotinib Hydrochloride (CP 358,774)FDA Link
02/2018 - 04/2005
10Docetaxel (Taxotere)FDA Link
02/2018 - 12/2005
9Proteins (Proteins, Gene)FDA Link
06/2022 - 05/2002
9Cetuximab (Erbitux)FDA Link
01/2018 - 02/2004
7PlatinumIBA
01/2021 - 11/2008
6Bevacizumab (Avastin)FDA Link
01/2022 - 04/2005
6Carboplatin (JM8)FDA LinkGeneric
01/2018 - 12/2005
6Paclitaxel (Taxol)FDA LinkGeneric
12/2013 - 05/2004
5brigatinibIBA
12/2022 - 08/2017
5AfatinibIBA
09/2022 - 01/2017
5Gefitinib (Iressa)FDA Link
12/2017 - 05/2007
5Insulin-Like PeptidesIBA
06/2015 - 05/2007
5lonafarnib (SCH 66336)IBA
08/2012 - 05/2004
4Immune Checkpoint InhibitorsIBA
09/2022 - 11/2020
4Monoclonal AntibodiesIBA
12/2013 - 12/2004
3pembrolizumabIBA
09/2022 - 04/2021
3Phosphotransferases (Kinase)IBA
06/2022 - 08/2012
3CrizotinibIBA
01/2020 - 08/2017
3LigandsIBA
01/2020 - 08/2011
3Cisplatin (Platino)FDA LinkGeneric
02/2018 - 01/2003
3DNA (Deoxyribonucleic Acid)IBA
11/2015 - 10/2004
3Insulin-Like Growth Factor I (IGF-1)IBA
05/2014 - 05/2007
3vandetanib (ZD6474)IBA
08/2012 - 01/2010
2ceritinibIBA
12/2022 - 05/2021
2alectinibIBA
12/2022 - 05/2021
2canakinumabFDA Link
09/2022 - 04/2021
2RNA (Ribonucleic Acid)IBA
11/2021 - 08/2019
2Anaplastic Lymphoma KinaseIBA
05/2021 - 08/2017
2Messenger RNA (mRNA)IBA
06/2015 - 11/2013
2Insulin ReceptorIBA
02/2015 - 05/2012
2Insulin (Novolin)FDA Link
02/2015 - 05/2012
2Insulin-Like Growth Factor II (Somatomedin A)IBA
05/2014 - 09/2009
2Sorafenib (BAY 43-9006)FDA Link
12/2013 - 06/2011
2Pemetrexed (MTA)FDA Link
12/2013 - 12/2005
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2012 - 04/2005
2TransferasesIBA
08/2012 - 05/2002
2Antineoplastic Agents (Antineoplastics)IBA
05/2012 - 02/2004
2Epidermal Growth Factor (EGF)IBA
08/2011 - 01/2003
2Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
08/2011 - 03/2008
2Cyclin D1IBA
08/2011 - 06/2011
2Bexarotene (LGD1069)FDA Link
06/2011 - 06/2011
2GemcitabineFDA Link
04/2010 - 02/2009
2Taxoids (Taxanes)IBA
04/2010 - 06/2002
2Celecoxib (Celebrex)FDA Link
02/2010 - 03/2009
2IGF Type 1 Receptor (IGF 1 Receptor)IBA
09/2009 - 03/2008
2RetinoidsIBA
01/2009 - 04/2006
2SurvivinIBA
03/2008 - 10/2006
2taxaneIBA
08/2005 - 05/2004
2Farnesyltranstransferase (Farnesyltransferase)IBA
08/2005 - 05/2004
1Antiviral Agents (Antivirals)IBA
01/2023
1Creatine Kinase (Creatine Phosphokinase)IBA
12/2022
1larotrectinibIBA
06/2022
1tyrosine receptor (receptor, tyrosine)IBA
06/2022
1TropomyosinIBA
06/2022
1Circulating Tumor DNAIBA
01/2022
1atezolizumabIBA
01/2022

Therapy/Procedure

48Therapeutics
12/2022 - 01/2002
22Drug Therapy (Chemotherapy)
01/2023 - 05/2002
14Chemoprevention
01/2018 - 01/2002
5Neoadjuvant Therapy
04/2021 - 11/2010
5Radiotherapy
01/2020 - 02/2004
3Immunotherapy
01/2023 - 09/2018
3Precision Medicine
01/2019 - 01/2008
2Surgical Amputation (Amputations)
06/2022 - 01/2017
2Drug Tapering
01/2020 - 03/2013
2Combined Modality Therapy
01/2018 - 06/2004